Analysts Have Lowered Expectations For Enovix Corporation (NASDAQ:ENVX) After Its Latest Results
Analysts Have Lowered Expectations For Enovix Corporation (NASDAQ:ENVX) After Its Latest Results
Enovix Corporation (NASDAQ:ENVX) just released its quarterly report and things are looking bullish. Results overall were solid, with revenues arriving 5.0% better than analyst forecasts at US$4.3m. Higher revenues also resulted in substantially lower statutory losses which, at US$0.13 per share, were 5.0% smaller than the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
納斯達克上市公司Enovix Corporation(NASDAQ:ENVX)剛發佈了季度報告,情況看好。總體來說,業績表現穩健,營業收入達到了430萬美元,比分析師預測高出5.0%。更高的營業收入也顯著降低了法定損失,每股0.13美元,比分析師預期的小了5.0%。分析師們通常會在每次業績後更新他們的預測,我們可以從他們的估計中判斷公司的情況是否有變化,或者是否有任何需要注意的新問題。我們已收集最新的法定預測,以查看分析師是否已調整了他們的盈利模型,以反映這些結果。
After the latest results, the eleven analysts covering Enovix are now predicting revenues of US$46.1m in 2025. If met, this would reflect a major 122% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 16% from last year to US$1.16. Before this latest report, the consensus had been expecting revenues of US$53.4m and US$1.14 per share in losses. So there's definitely been a change in sentiment in this update, with the analysts administering a substantial haircut to next year's revenue estimates, while at the same time holding losses per share steady.
根據最新的結果,覆蓋Enovix的十一名分析師預測2025年的營業收入將達到4610萬美元。如果達成,這將反映出與過去12個月相比,營收明顯提高了122%。預計損失將得到控制,較去年減少16%,至1.16美元。在此最新報告發布之前,市場預期的營業收入爲5340萬美元,每股損失爲1.14美元。因此,在這次更新中情緒明顯有所變化,分析師大幅削減了明年的營收預期,同時保持每股損失穩定。
There was no real change to the average price target of US$28.58, suggesting that the revisions to revenue estimates are not expected to have a long-term impact on Enovix's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Enovix analyst has a price target of US$100.00 per share, while the most pessimistic values it at US$14.00. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
對於28.58美元的平均目標價並沒有真正變化,表明營收預測的修訂不太可能對Enovix的估值產生長期影響。共識目標價只是個別分析師目標的平均值,因此,看一下底層估算範圍有可能很有幫助。最樂觀的Enovix分析師給出的目標價爲每股100.00美元,而最悲觀的值爲每股14.00美元。在這種情況下,我們可能會較少看重分析師的預測,因爲這麼廣泛的估算範圍可能暗示着這家公司的未來很難準確評估價值。因此,基於共識目標價做決策可能不是一個好主意,畢竟這只是這一系列估算的平均值。
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We can infer from the latest estimates that forecasts expect a continuation of Enovix'shistorical trends, as the 89% annualised revenue growth to the end of 2025 is roughly in line with the 77% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.5% per year. So although Enovix is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
我們可以將這些估算放在更大的背景下來看,比如預測與過去表現的對比,以及預測相對於行業其他公司更看好還是更謹慎。從最新的預測中我們可以推斷,預測預計Enovix的歷史趨勢將繼續,因爲到2025年底的89%年化營業收入增長大致與過去五年的77%年增長率相當。相比之下,我們的數據表明,同行業其他(有分析師覆蓋)公司的預測顯示,預計他們的營業收入每年增長8.5%。因此,儘管Enovix預計將保持營收增長率,但肯定預計將比更廣泛的行業增長速度更快。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. They also downgraded Enovix's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
最重要的是分析師們重申了他們對明年每股虧損的估算。他們還下調了Enovix的營收預期,但行業數據表明預計它將比更廣泛的行業增長更快。共識目標價格沒有實質性變化,表明業務的內在價值在最新預測中沒有發生重大變化。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Enovix analysts - going out to 2026, and you can see them free on our platform here.
話雖如此,公司盈利的長期軌跡比明年更重要。我們有來自多位Enovix分析師的估算,延伸至2026年,您可以在我們的平台上免費查看。
And what about risks? Every company has them, and we've spotted 4 warning signs for Enovix you should know about.
那風險呢?每家公司都有風險,我們已經發現Enovix存在4個警示信號,您應該了解。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。